NC
FATE icon

NewSquare Capital’s Fate Therapeutics FATE Stock Holding History

NewSquare Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-60
Closed -$286 – 682
2023
Q2 		$286 Hold
60
– – ﹤0.01% 737
2023
Q1 		$342 Hold
60
– – ﹤0.01% 745
2022
Q4 		$605 Buy
+60
New +$1.13K ﹤0.01% 634

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NewSquare Capital's FATE Position: Q3 2023 in Review

NewSquare Capital sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 60 shares — an estimated $286 sold.

NewSquare Capital first reported a position in FATE in Q4 2022 and held it in 3 quarters. The position peaked at $605 in Q4 2022. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • NewSquare Capital reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 60 Fate Therapeutics shares in Q3 2023, an estimated $286.
  • NewSquare Capital first reported a position in Fate Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Fate Therapeutics position peaked at $605 in Q4 2022.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.